http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114621351-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-74 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate | 2022-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114621351-B |
| titleOfInvention | Multispecific antibodies and their use in the treatment of cancer |
| abstract | The invention provides a multispecific antibody and its use for treating cancer, comprising a first antigen-binding domain specifically binding to a first antigen, a second antigen-binding domain specifically binding to a second antigen, and a third antigen specifically binding The third antigen-binding domain has a single-domain antibody structure; the antibody has a brand-new CDR region, in which the first antigen-binding domain targeting EGFR can bind to the target antigen with high affinity, improving the target antigen recognized by tumor cells. tropism, while the second antigen-binding domain targeting CD3 chooses a single-domain antibody structure with moderately strong affinity, which can not only effectively mediate T cell immune response, but also prevent bispecific antibodies from accumulating in the spleen, lymph nodes, etc. The anti-tumor effect is affected by the enriched tissue of cells; the 4-1BB co-stimulatory factor is introduced into the structure of the bispecific antibody, so that the effector cells can be activated through the dual signaling pathway of CD3 and 4-1BB to exert a greater anti-tumor effect The antigen-binding domains are all in the form of single-domain antibodies, which can reduce the difficulty of drug delivery in vivo; the antigen-binding domain targeting EGFR and the antigen-binding domain targeting CD3 are set at a ratio of 2:1, which helps to capture tumor cells in vivo, Improve the specificity of treatment and reduce off-target effects; in addition, the multispecific antibody provided in the present invention can also reduce the excessive secretion of immune factors during treatment, helping to reduce toxic and side effects. |
| priorityDate | 2022-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 286.